S00868254 - Scrip Top
Date published: 30 December 2004
Xyzal approved in EU for persistent allergic rhinitis:
UCB's antihistamine, Xyzal (levocetirizine, licensed from Sepracor), has been approved in the 15 member states that made up the old EU plus Norway for use in patients with persistent allergic rhinitis via the mutual recognition procedure. The expanded indication is based on the results of the XPERT trial - a six-month study in 551 patients with persistent allergic rhinitis which found that levocetirizine was more effective than placebo in relieving symptoms throughout the duration of the study. The product also improved quality of life and decreased the costs of the disease on society, UCB says. Xyzal is the first antihistamine to receive approval for six months' continuous treatment, it adds. The new indication should help boost sales of the product, which is one of the key growth drivers for the firm. Xyzal is already approved in Europe for allergic rhinitis, and for chronic idiopathic urticaria in adults and children over six years old.
Full title: SCRIP - World Pharmaceutical News - www.scrippharma.com
FILED 30 December 2004 COPYRIGHT Informa UK Ltd 2004 [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-03-24 14:07